Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arava “Authorized” Generic Will Be Distributed By Prasco

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi-Aventis will supply leflunomide to Prasco, which will distribute the rheumatoid arthritis therapy when other Arava generics enter the market.

You may also be interested in...



First-Time Generics Of Sanofi-Aventis’ Arava Enter Market

FDA appears to have denied Sanofi’s March citizen petition requesting refusal to approve ANDAs without certain bioequivalence studies.

First-Time Generics Of Sanofi-Aventis’ Arava Enter Market

FDA appears to have denied Sanofi’s March citizen petition requesting refusal to approve ANDAs without certain bioequivalence studies.

Prasco To Launch Allegra “Authorized” Generic

Licensed version of Sanofi-Aventis’ antihistamine will begin shipping more than two weeks after Teva’s fexofenadine generic launched “at risk.”

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS062620

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel